Study: CCTG-PR26 - A RANDOMIZED PHASE III CLINICAL TRIAL FOR THE ADDITION OF DOCETAXEL TO ANDROGEN RECEPTOR PATHWAY INHIBITORS IN PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER AND SUBOPTIMAL PSA RESPONSE (TRIPLE-SWITCH)
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 5 to 7 business days.
Please understand that:
Thanks again. Volunteers such as yourself are at the core of our work.